Alembic Pharma Gets USFDA Nod for Generic Bromfenac Ophthalmic Solution
By Rediff Money Desk, New Delhi Jul 09, 2024 14:13
Alembic Pharmaceuticals receives USFDA approval for its generic Bromfenac ophthalmic solution, indicated for post-cataract surgery inflammation and pain treatment.
![Alembic Pharma Gets USFDA Nod for Generic Bromfenac Ophthalmic Solution](https://im.rediff.com/money/2012/oct/28drug.jpg)
New Delhi, Jul 9 (PTI) Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic Bromfenac ophthalmic solution, which is indicated for the treatment of postoperative inflammation and pain in patients who have undergone cataract surgery.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Prolensa Ophthalmic Solution, 0.07 per cent of Bausch & Lomb Incorporated (Bausch), it added.
Bromfenac Ophthalmic Solution 0.07 per cent is a Nonsteroidal Anti-inflammatory Drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, the company said.
It has an estimated market size of USD 168 million for 12 months ended March 2024, Alembic said citing IQVIA data.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Prolensa Ophthalmic Solution, 0.07 per cent of Bausch & Lomb Incorporated (Bausch), it added.
Bromfenac Ophthalmic Solution 0.07 per cent is a Nonsteroidal Anti-inflammatory Drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, the company said.
It has an estimated market size of USD 168 million for 12 months ended March 2024, Alembic said citing IQVIA data.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Cipla Faces Rs...](https://im.rediff.com/80-80/money/2020/oct/01tax.jpg)
Cipla Faces Rs 773 Crore I-T Demand: Details -...
Cipla receives a Rs 773.44 crore demand notice from the income tax department for...
![EV Segment Growth...](https://im.rediff.com/80-80/money/2023/jun/19ev.jpg)
EV Segment Growth Needs Long-Term Policy...
Lohia CEO Ayush Lohia emphasizes the need for long-term policy support, including FAME...
![Gold Price Rises...](https://im.rediff.com/80-80/money/2015/jul/01gold.jpg)
Gold Price Rises Rs 550, Silver Jumps Rs 400 |...
Gold prices surged by Rs 550 to Rs 75,700 per 10 grams on Tuesday, driven by strong...